Suven Life Sciences has been granted patent by Australia, China, Europe, South Korea and the US for a drug used in the treatment of neuro-degenerative diseases. The patents are valid until 2031, 2030, 2031, 2030 and 2031, respectively, Suven Life Sciences. The grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
Company Profile : Suven Life Sciences Ltd
Leave a Reply